{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:37:12Z","timestamp":1793731032683,"version":"4.6.1"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"44","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,31]]},"abstract":"<jats:p>The heterogeneity of pancreatic adenocarcinoma (PAAD) tumors is complex. The purpose of this work was to use immunologic signature gene sets (ISGS) activity alterations to identify subtypes of PAAD and to develop valid prognostic indicators. We discovered tumor-related differentially expressed gene sets and their associated subtypes by analyzing changes in ISGS activity via the cancer genome Atlas and the genotype-tissue expression datasets. To evaluate the relationship between these subtypes and clinical characteristics, the immunological microenvironment, and tumor immune dysfunction and exclusion, we conducted survival studies. Furthermore, we identified subtype-specific gene sets and developed a prognostic risk score (RS) model and a corresponding nomogram. The robustness and generalizability of the RS model were validated using the gene expression omnibus dataset. Additionally, differences in drug sensitivity and tumor mutation burden were compared between risk groups. On the basis of variations in ISGS activity, 2 subtypes of PAAD were distinguished. The prognosis is worse for subtype 1 patients, and there is no statistically significant difference between the clinicopathologic characteristics of the 2 subtypes. However, subtype 1 patients do not respond well to immunotherapy, and the immunological microenvironment varies significantly across subtypes. Additionally, patients were assigned to distinct risk groups by a prognostic RS model based on differentially expressed genes linked to both subtypes. Individuals belonging to distinct risk categories exhibited varying degrees of medication sensitivity; high-risk patients also had shorter survival periods and greater tumor mutation burden. For patients with pancreatic cancer, nomograms that include RS and clinicopathologic variables are may provide useful tools. Our research used the ISGS to identify subtypes of PAAD and created prognostic RS models. Through the integration of the RS and clinicopathological parameters into nomograms, prognostic prediction may be reinforced, and may provide new perspectives for future personalized treatment strategies.<\/jats:p>","DOI":"10.1097\/md.0000000000045385","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T17:00:54Z","timestamp":1763571654000},"page":"e45385","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Identification of pancreatic subtypes and prognostic markers on the basis of changes in immunologic signature gene sets activity"],"prefix":"10.1097","volume":"104","author":[{"given":"Junwei","family":"Fang","sequence":"first","affiliation":[{"name":"Department of General Surgery, 900th Hospital of Joint Logistics Support Force, PLA, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of General Surgery, 900th Hospital of Joint Logistics Support Force, PLA, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiping","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, 900th Hospital of Joint Logistics Support Force, PLA, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixiang","family":"Ni","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Fuzong Clinical Medical College of Fujian Medical University, 900th Hospital of Joint Logistics Support Force, PLA, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhao","family":"Du","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Dongfang Hospital of Xiamen University, School of Medicine, Xiamen University, 900th Hospital of Joint Logistics Support Force, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibin","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Dongfang Hospital of Xiamen University, School of Medicine, Xiamen University, 900th Hospital of Joint Logistics Support Force, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8906-4970","authenticated-orcid":false,"given":"Meili","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Urology, Fuzhou First General Hospital, Fuzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260520","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer: a review.","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"key":"R2-20260520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2021.06.027","article-title":"Advances in the epidemiology of pancreatic cancer: trends, risk factors, screening, and prognosis.","volume":"520","author":"Cai","year":"2021","journal-title":"Cancer Lett"},{"key":"R3-20260520","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41575-021-00457-x","article-title":"Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors.","volume":"18","author":"Klein","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R4-20260520","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1186\/s12889-024-17875-6","article-title":"Global burden of pancreatic cancer attributable to metabolic risks from 1990 to 2019, with projections of mortality to 2030.","volume":"24","author":"He","year":"2024","journal-title":"BMC Public Health"},{"key":"R5-20260520","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12885-023-10675-y","article-title":"Integrated transcriptional analysis reveals macrophage heterogeneity and macrophage-tumor cell interactions in the progression of pancreatic ductal adenocarcinoma.","volume":"23","author":"Yang","year":"2023","journal-title":"BMC Cancer"},{"key":"R6-20260520","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1158\/1078-0432.CCR-18-1955","article-title":"Single cell transcriptomics of pancreatic cancer precursors demonstrates epithelial and microenvironmental heterogeneity as an early event in neoplastic progression.","volume":"25","author":"Bernard","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R7-20260520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2019.00246","article-title":"Pancreatic cancer heterogeneity can be explained beyond the genome.","volume":"9","author":"Juiz","year":"2019","journal-title":"Front Oncol"},{"key":"R8-20260520","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13073-022-01138-3","article-title":"Therapy sculpts the complex interplay between cancer and the immune system during tumour evolution.","volume":"14","author":"Thol","year":"2022","journal-title":"Genome Med"},{"key":"R9-20260520","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions.","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"key":"R10-20260520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2024.1383978","article-title":"Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application.","volume":"15","author":"Zheng","year":"2024","journal-title":"Front Immunol"},{"key":"R11-20260520","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer.","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"key":"R12-20260520","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1158\/1078-0432.CCR-19-1467","article-title":"Purity Independent Subtyping of Tumors (PurIST), a clinically robust, single-sample classifier for tumor subtyping in pancreatic cancer.","volume":"26","author":"Rashid","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R13-20260520","doi-asserted-by":"crossref","first-page":"6491","DOI":"10.1158\/1078-0432.CCR-21-1907","article-title":"Prognostic relevance of pancreatic adenocarcinoma whole-tumor transcriptomic subtypes and components.","volume":"27","author":"Zhao","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R14-20260520","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00432-023-05573-6","article-title":"Prognosis and immunotherapy response prediction based on M2 macrophage-related genes in colon cancer.","volume":"150","author":"Xu","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"R15-20260520","doi-asserted-by":"crossref","first-page":"pbac010","DOI":"10.1093\/pcmedi\/pbac010","article-title":"A novel immunogenomic signature to predict prognosis and reveal immune infiltration characteristics in pancreatic ductal adenocarcinoma.","volume":"5","author":"Li","year":"2022","journal-title":"Precis Clin Med"},{"key":"R16-20260520","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12943-020-1141-9","article-title":"Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy.","volume":"19","author":"Zhong","year":"2020","journal-title":"Mol Cancer"},{"key":"R17-20260520","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data.","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinf"},{"key":"R18-20260520","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies.","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"R19-20260520","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","article-title":"ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking.","volume":"26","author":"Wilkerson","year":"2010","journal-title":"Bioinformatics"},{"key":"R20-20260520","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","article-title":"TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells.","volume":"77","author":"Li","year":"2017","journal-title":"Cancer Res"},{"key":"R21-20260520","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/978-1-4939-7493-1_12","article-title":"Profiling tumor infiltrating immune cells with CIBERSORT.","volume":"1711","author":"Chen","year":"2018","journal-title":"Methods Mol Biol"},{"key":"R22-20260520","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/bs.mie.2019.05.056","article-title":"Deconvoluting tumor-infiltrating immune cells from RNA-seq data using quanTIseq.","volume":"636","author":"Plattner","year":"2020","journal-title":"Methods Enzymol"},{"key":"R23-20260520","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13148-019-0730-1","article-title":"Statistical predictions with glmnet.","volume":"11","author":"Engebretsen","year":"2019","journal-title":"Clin Epigenetics"},{"key":"R24-20260520","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1101\/gr.239244.118","article-title":"Maftools: efficient and comprehensive analysis of somatic variants in cancer.","volume":"28","author":"Mayakonda","year":"2018","journal-title":"Genome Res"},{"key":"R25-20260520","doi-asserted-by":"crossref","first-page":"bbab260","DOI":"10.1093\/bib\/bbab260","article-title":"oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data.","volume":"22","author":"Maeser","year":"2021","journal-title":"Brief Bioinform"},{"key":"R26-20260520","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/cac2.12067","article-title":"A nomogram for predicting overall survival in patients with low-grade endometrial stromal sarcoma: a population-based analysis.","volume":"40","author":"Wu","year":"2020","journal-title":"Cancer Commun (Lond)"},{"key":"R27-20260520","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/SLA.0000000000002753","article-title":"Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection.","volume":"270","author":"Gemenetzis","year":"2019","journal-title":"Ann Surg"},{"key":"R28-20260520","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1200\/JCO.19.02274","article-title":"Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the dutch randomized phase III PREOPANC trial.","volume":"38","author":"Versteijne","year":"2020","journal-title":"J Clin Oncol"},{"key":"R29-20260520","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11523-023-00950-0","article-title":"Precision oncology in pancreatic cancer: experiences and challenges of the CCCMunichLMU molecular tumor board.","volume":"18","author":"Dorman","year":"2023","journal-title":"Target Oncol"},{"key":"R30-20260520","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s40164-021-00252-z","article-title":"Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies.","volume":"10","author":"Zhu","year":"2021","journal-title":"Exp Hematol Oncol"},{"key":"R31-20260520","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41571-019-0222-4","article-title":"Tumour-associated neutrophils in patients with cancer.","volume":"16","author":"Shaul","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"R32-20260520","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3390\/cancers16050981","article-title":"Dendritic cells in cancer immunology and immunotherapy.","volume":"16","author":"Hato","year":"2024","journal-title":"Cancers (Basel)"},{"key":"R33-20260520","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.it.2016.09.006","article-title":"Dendritic cells and cancer immunity.","volume":"37","author":"Gardner","year":"2016","journal-title":"Trends Immunol"},{"key":"R34-20260520","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(18)30789-X","article-title":"International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.","volume":"391","author":"Pag\u00e8s","year":"2018","journal-title":"Lancet"},{"key":"R35-20260520","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/cjp2.192","article-title":"Immune cell infiltrates as prognostic biomarkers in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.","volume":"7","author":"McGuigan","year":"2021","journal-title":"J Pathol Clin Res"},{"key":"R36-20260520","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.","volume":"30","author":"Chan","year":"2019","journal-title":"Ann Oncol"},{"key":"R37-20260520","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy.","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"R38-20260520","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition.","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"key":"R39-20260520","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-020-00958-3","article-title":"Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.","volume":"13","author":"Qian","year":"2020","journal-title":"J Hematol Oncol"},{"key":"R40-20260520","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13046-018-0705-7","article-title":"New therapeutic strategies to treat human cancers expressing mutant p53 proteins.","volume":"37","author":"Blandino","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"R41-20260520","doi-asserted-by":"crossref","first-page":"e2300708","DOI":"10.1002\/advs.202300708","article-title":"Transforming growth factor beta promotes inflammation and tumorigenesis in Smad4-deficient intestinal epithelium in a YAP-dependent manner.","volume":"10","author":"Liu","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"R42-20260520","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1158\/2159-8290.CD-18-0275","article-title":"Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine.","volume":"8","author":"Aguirre","year":"2018","journal-title":"Cancer Discov"},{"key":"R43-20260520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tranon.2015.11.007","article-title":"Prognostic value of SMAD4 in pancreatic cancer: a meta-analysis.","volume":"9","author":"Shugang","year":"2016","journal-title":"Transl Oncol"},{"key":"R44-20260520","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.3390\/cancers17111896","article-title":"Impact of long-term chemotherapy on outcomes in pancreatic ductal adenocarcinoma: a real-world UK multi-centre study.","volume":"17","author":"Mahmood","year":"2025","journal-title":"Cancers (Basel)"},{"key":"R45-20260520","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11010-020-03796-6","article-title":"Bcl-2\/Bcl-xL inhibitor navitoclax increases the antitumor effect of Chk1 inhibitor prexasertib by inducing apoptosis in pancreatic cancer cells via inhibition of Bcl-xL but not Bcl-2.","volume":"472","author":"Morimoto","year":"2020","journal-title":"Mol Cell Biochem"},{"key":"R46-20260520","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial.","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000045385","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:02:55Z","timestamp":1779274975000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000045385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":46,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045385","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"2025-07-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}